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Carbapenemases may be defined as b-lactamases that significantly hydrolyze at least
imipenem or/and meropenem. Carbapenemases involved in acquired resistance are of
Ambler molecular classes A, B, and D. Class A, clavulanic acid-inhibited carbapenemases
are rare. They are either chromosomally encoded (NMC-A, Sme-1 to Sme-3, IMI-1) in
Enterobacter cloacae and Serratia marcescens, or plasmid encoded, such as KPC-1 in
Klebsiella pneumoniae and GES-2 in Pseudomonas aeruginosa, the latter being a point-mutant
of the clavulanic acid-inhibited extended-spectrum b-lactamase GES-1. The class B
enzymes are the most clinically significant carbapenemases. They are metalloenzymes
of the IMP or VIM series. They have been reported worldwide but mostly from South East
Asia and Europe. Metalloenzymes, whose genes are plasmid and integron located,
hydrolyze virtually all b-lactams except aztreonam. Finally, the class D carbapenemases
are increasingly reported in Acinetobacter baumannii but compromise imipenem and
meropenem susceptibility only marginally. The sources of the acquired carbapenemase
genes remain unknown, as does the relative importance of the spread of epidemic strains
as opposed to the spread of plasmid- or integron-borne genes. Because most of these
carbapenemases confer only reduced susceptibility to carbapenems in Enterobacteria-
ceae, they may remain underestimated as a consequence of the lack of their detection.
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I N T R O D U C T I O N
Reports of carbapenemases have been increasing
over the last few years. This phenotypic grouping
of enzymes is a heterogeneous mixture of b-lacta-
mases belonging to molecular Ambler class A
(penicillinases), class B (metalloenzymes) and
class D (oxacillinases). These enzymes have the
common property of hydrolyzing, at least par-
tially, imipenem or meropenem together with
other penicillin or cephalosporin antibiotics.
Metalloenzymes have been described as natu-
rally occurring in several Gram-positive and
Gram-negative bacterial species, such as Bacillus
cereus, Stenotrophomonas maltophilia, Flavobacterium
and Chryseobacterium species, Aeromonas hydrophila,
Legionella gormanii and Janthinobacterium lividum
[1–10]. The metalloenzymes are clavulanic acid
resistant and susceptible to inhibition by divalent
ion chelators such as EDTA. In Chryseobacterium
meningosepticum, two unrelated class B carbapene-
mases are naturally expressed [8,9]. The naturally
occurring class B enzymes are chromosomally
encoded [10]. However, it has been found recently
that the L-1 carbapenemase of Stenotrophomonas
maltophilia might also be encoded by large plas-
mids (200 kb) [11]. None of these carbapenemases
identified as naturally occurring mechanisms of
resistance to carbapenems has been identified so
far in acquired resistance.
T H E A M B L E R C L A S S
A C A R B A P E N E M A S E S
A few Ambler class A carbapenemases have been
reported in rare enterobacterial isolates. They
belong to the group 2f as defined by Bush et al.
[12] and may form part of the so-called clavulanic
acid-inhibited penicillinase group.
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NMC-A was the first class A carbapenemase
identified, from an Enterobacter cloacae clinical iso-
late NOR-1 in 1990 [13]. This strain was from a
patient in a French hospital who had been treated
with one intravenous bolus (500 mg) of imipenem
[13]. E. cloacae NOR-1 had decreased susceptibility
to imipenem, aztreonam and less so to merope-
nem, whereas it remained fully susceptible to
extended-spectrum cephalosporins. NMC-A sig-
nificantly hydrolyzes aminocarboxypenicillins,
cephalothin, imipenem, and aztreonam (Table 1).
Its activity is partially inhibited by clavulanic acid,
tazobactam and sulbactam, as for most of the
enzymes of the penicillinase group. NMC-A is
distantly related to extended-spectrum penicilli-
nases such as the derivatives of the TEM and SHV
series. The NMC-A gene is chromosomally
encoded. Expression of NMC-A was inducible
[14]. Indeed, the blaNMC-A gene was preceded by
a LysR-type regulatory gene similar to those found
upstream of the naturally encoded cephalospori-
nase (AmpC-type) genes. The LysR-type regulator
named NMC-R increases biosynthesis of the
enzyme at a basal state and further increases its
biosynthesis when b-lactam-mediated induction
occurs [14]. We have shown recently that nucleo-
tide substitutions in another gene, the ampD gene
coding for an amidase (an enzyme involved in
peptidoglycan biosynthesis), may co-regulate and
lead to stable coexpression of the carbapenemase
NMC-A together with overexpression of the natu-
rally occurring AmpC-type enzyme of Enterobacter
cloacae [15].
SME-1 has been identified from two Serratia
marcescens isolates collected in London in 1982
prior to any carbapenem marketing [16]. These
strains were resistant to amino-, carboxy- and
ureidopenicillins, early-generation cephalospor-
ins, imipenem and aztreonam. Although SME-1
shares only 68% amino acid identity with NMC-A
[17], it had an overall similar hydrolysis profile. Its
expression, like that of NMC-A, is also regulated
by a LysR-type regulator but to a minor extent [18].
It is possible that S. marcescens isolates that have a
blaSME gene are Serratia marcescens subspecies that
naturally encode this resistance determinant.
Recently, SME-2 and SME-3 b-lactamases that
are point-mutant derivatives of SME-1 have been
identified from S. marcescens strains isolated in
several geographic locations in the USA [19].
Genomic comparison of worldwide-encountered
S. marcescens isolates that have SME-like enzymes
suggests a global dissemination of a distinct S.
marcescens subtype [20].
IMI-1 was the third type of chromosomally
encoded carbapenemase of Ambler class A iden-
tified from two E. cloacae strains isolated in South-
ern California in 1984 [21]. IMI-1 shares 95% amino
acid identity with NMC-A, has a very similar
hydrolysis profile and is inducible, due to an
upstream-located LysR-type regulatory gene.
More recently, a totally novel class A enzyme,
KPC-1, has been reported from a Klebsiella pneu-
moniae isolate from the USA that was resistant to
carbapenems, extended-spectrum cephalosporins
and aztreonam (Table 1) [22]. Compared to the
chromosome-encoded class A carbapenemases,
KPC-1 activity is more inhibited by clavulanic acid
and tazobactam, whereas its expression is not
inducible. KPC-1 has weak amino acid identity
with the most closely related enzymes SME-1
(45%), NMC-A (44%) and IMI-1 (43%). It hydro-
lyzes penicillins, first- and second-generation
cephalosporins, aztreonam and carbapenems
(meropenem as well as imipenem). Most of the
amino acids putatively involved in the carbapene-
mase activity of chromosomally encoded class A
carbapenemases (C69, S70, K73, S130, R164, E166,
N170, D179, R220, K234 and C238 [22,23]) are
found in its amino acid sequence, except for
H105 and S237 instead of W105 and T237, respec-
tively [22]. The discovery of blaKPC-1 represents an
additional threat in the evolving world of b-lacta-
mase-mediated resistance in bacteria, since it was
encoded by a 50-kb transferable plasmid of an
enterobacterial species understood to be the source
of well-known and worldwide extended-spectrum
b-lactamases.
The most recently reported class A enzyme with
carbapenemase activity is GES-2, which is a point-
mutant derivative of the extended-spectrum b-
lactamase GES-1 [24]. GES-2 was identified from
a Pseudomonas aeruginosa isolate in South Africa
[24]. GES-2, like GES-1, possesses cysteine residues
in positions 69 and 238 that may form a disulfide
bridge and that may explain the imipenem-bind-
ing properties [23,24]. GES-2 differs from GES-1 by
a Gly-to-Asp substitution in Ambler position 170,
located inside the omega loop. The omega loop
(amino acid residues 162–179) is rather conserved
in class A enzymes and may form the basis of their
catalytic site. Kinetic analysis showed that GES-2
catalytic efficiency against imipenem was 100-fold
higher than that of GES-1. However, GES-2 activity
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Table 1 Main features of acquired carbapenemases
Hydrolysis spectrum Inhibited by
Ambler
classification
Type of
enzymes
Amino-
penicillins
Ureido-
penicillins
Extended-
spectrum
Cephalosporins Aztreonam Carbapenems
Chavulamic
acid EDTA Organisms
Genetic
location
A NmcA;
Sme-1
to Sme-3;
IMI-1
f & ~ & f  – E. cloacae;
S. marcescens
Chromosomal
A KPC-1 f f & f f þ – K. pneumoniae Plasmid
A GES-2 f f f f & þ – P. aeruginosa Plasmid;
integron
B IMP-1 to
IMP-9
f f f ~ f – þ Enterobacteriaceae;
Pseudomonaceae,
Alcaligenes sp.;
Acinetobacter sp.
Chromosomal;
plasmid
Integron
B VIM-1 to
VIM-3
f f f ~ f – þ P. aeruginosa;
P. putida;
Acinetobacter
baumannii
Chromosomal;
plasmid;
integron
D OXA-23 to
OXA-27
f & f ~ &  – Acinetobacter
baumannii
Chromosomal;
 integron

f

High level; (&) low level; (~) no hydrolysis.

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against carbapenems remains 1000-fold less than
that of SME-1 and NMC-A. GES-2 identification
showed that class A extended-spectrum b-lacta-
mases may become weak carbapenemases
through a single amino acid substitution. Like
blaKPC-1, blaGES-2 was located on a large-size plas-
mid and on a class 1 integron.
Plasmid-mediated class A enzymes with carba-
penemase activity may become clinically signifi-
cant in species that naturally possess (e.g. E.
cloacae, P. aeruginosa) or acquire additional
mechanisms of carbapenem resistance such as
low permeability and/or efflux.
T H E A M B L E R C L A S S B
M E T A L L O E N Z Y M E S
IMP-1 was the first carbapenemase identified as a
source of acquired resistance to carbapenems in a
S. marcescens isolate in 1991 in Japan [25]. IMP-1,
like most metallocarbapenemases, has a very
broad substrate profile, including expanded-spec-
trum cephalosporins (cefotaxime, ceftazidime,
cefepime) and carbapenems (imipenem, merope-
nem, panipenem). Only the monobactams are not
hydrolyzed (Table 1). This metallo-b-lactamase is a
binuclear zinc-dependent enzyme whose activity
is susceptible to EDTA, whereas it is not inhibited
by clavulanic acid, tazobactam, and sulbactam
[26]. The same blaIMP-1 gene has also been char-
acterized from several aerobic and aerobic/anae-
robic Gram-negative species from patients
hospitalized in Japan; Enterobacteriaceae, P. aeru-
ginosa, Brevium diminuta, Pseudomonas fluorescens,
Burkholderia cepacia, Achromobacter (Alcaligenes)
xylosoxydans, Pseudomonas putida and Acinetobacter
baumannii [26–29]. These reports suggested hori-
zontal transfer of blaIMP-1, particularly among P.
aeruginosa and S. marcescens isolates, and/or
repeated introduction into clinical settings from
the environment. Senda et al. studied a total of
3700 P. aeruginosa isolates collected from 17 uni-
versity hospitals in Japan from 1992 to 1994 [27].
They showed that 15 of 132 carbapenem-resistant
P. aeruginosa isolates carried blaIMP-like genes [27].
Acquisition of these genes is not always followed
by expression of a high level of resistance to
carbapenems [27,28]. The blaIMP genes were often
located on large-size plasmids transferable to
Enterobacteriaceae. In a Japanese survey con-
ducted in 1996–97, IMP-1-producing isolates
accounted for 1.3% and 4.4% of S. marcescens
and P. aeruginosa isolates, respectively [30]. The
same authors also detected blaIMP-1 in Escherichia
coli and Citrobacter freundii isolates.
Genetic analysis of the blaIMP-1 environment
revealed typical features of integron-located
genes, in particular cassette boundaries known
as core sites and inverse core sites, defining gene
cassettes. Integrons are genetic structures capable
of integrating individual gene cassettes encoding
antibiotic resistance genes. The gene cassettes are
defined by a resistance gene preceded by a ribo-
somal binding site, and a recombination site,
known as the 59-base element (59-be), located
downstream of the integrated gene [31]. The
blaIMP-1 gene cassette was found to be inserted into
three different classes of integrons. Arakawa et al.
studied another S. marcescens isolate from Japan
producing the same enzyme [32]. They also found
an integron-like element carrying the blaIMP gene
cassette. However, the integrase gene and the
typical 59-be usually found downstream of blaIMP
were quite different. The putative integrase had
only 61% amino acid identity with that of a typical
class 1 integron. This was the first description of a
class 3 integron in which blaIMP was associated
with an aac(60)-Ib gene cassette encoding amino-
glycoside resistance. In that case, the blaIMP-con-
taining integron was located on a large plasmid.
In another study, blaIMP-1 was located on a 36-kb
plasmid and was part of a gene cassette inserted
into a class 1 integron, In31, in P. aeruginosa [32,33].
In31 belongs to a group of defective transposon
derivatives that originated from Tn402-like ances-
tors such as In0, In2 and In5. It comprises four
additional gene cassettes (aacA4, catB6, orfN, qacG)
(Figure 1) conferring resistance to aminoglyco-
sides, chloramphenicol and quaternary ammo-
nium compounds. IMP-1 is often found in
Japanese isolates and it has recently been identi-
fied in isolates from other countries, especially
from Europe. In 1999, Cornaglia et al. reported
an IMP-1-producing Acinetobacter baumannii iso-
late from an Italian patient [34].
IMP-2 was found also from an A. baumannii
isolate from Italy isolated in 1997 [35]. BlaIMP-2
was integron-borne but its 59-be was not related
to that of blaIMP-1, indicating a different origin of
gene cassettes encoding these two b-lactamase
variants. The blaIMP-2-positive integron carried a
DNA integrase gene typical of class 1 integrons and,
in addition to the blaIMP-2 gene cassette, aacA4 and
aadA1 gene cassettes expressing aminoglycoside
 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 8, 321–331
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resistance. IMP-2 shares 85% amino acid identity
with IMP-1, with none of the amino acid changes
occurring among highly conserved residues of
class B enzymes [35,36]. The kinetic parameters
of IMP-2 are similar to those of IMP-1 for many b-
lactam substrates, but differ particularly for ampi-
cillin, carbenicillin, cephaloridin, and meropenem.
IMP-3 (previously named MET-1) was identi-
fied in a Shigella flexneri isolate from Japan [37].
This enzyme was encoded on a transferable plas-
mid by a class 1 integron-located gene. IMP-3
differs from IMP-1 by two amino acid changes.
The Gly-to-Ser change at position 262 (class B BBL
numbering [36]) in IMP-3 may restrict its substrate
profile [37]. Indeed, IMP-3 does not significantly
hydrolyze benzylpenicillin, ampicillin, ceftazi-
dime, and imipenem. Therefore, it has been sug-
gested that IMP-3 may be a progenitor of IMP-1
[38]. Identification of IMP-3 in S. flexneri signals the
ongoing spread of metallocarbapenemases among
community-acquired pathogens.
IMP-4 has been characterized from Acinetobacter
isolates recovered from blood samples in Hong
Kong between 1994 and 1998 [39]. These isolates
were resistant to most b-lactams, including imipe-
nem (MIC from 8 to 32 mg/L). IMP-4 has also been
found in a Citrobacter youngae isolate obtained in
1998 in Hong Kong [40]. In that case, blaIMP-4 was
plasmid-borne and could be transferred by con-
jugation from C. youngae to E. coli. This report
underlined the spread of these carbapenemase
genes in enterobacterial isolates as a consequence
of their plasmid location.
From 2000 to 2001, additional IMP variants were
identified in several clinical strains of Gram-nega-
tive aerobes throughout the world (Table 2). They
are often available only as accession numbers in
the GenBank databases. BlaIMP-5 has been found in
an A. baumannii isolate from Portugal, blaIMP-6 in a
S. marcescens isolate from Japan [41], blaIMP-7 in a P.
aeruginosa isolate as a source of a nosocomial
outbreak in Thailand, blaIMP-8 in a K. pneumoniae
isolate from Taiwan [42], and blaIMP-9 in a P.
aeruginosa isolate from China. In fact, IMP-like
enzymes may now be divided into three major
subgroups (Figure 2). The first subgroup includes
IMP-1 and IMP-3 to 7, and the percentage of
amino acid identity in this group ranges from 90%
to 99%. The second subgroup includes IMP-2 and
IMP-8, which differ by only two amino acid resi-
dues. The amino acid identity between these two
subgroups ranges from 84% to 88%. BlaIMP-9
reported from a P. aeruginosa isolate in Japan
may be the unique representative of a third group,
IMP-9 sharing 87% and 86% amino acid identity
with IMP-1 and IMP-2, respectively. The genetic
support of these novel blaIMP genes is unknown.
VIM-1 was reported in Verona in Italy from a P.
aeruginosa isolate in 1997 [43]. It was the first
example of a representative of a novel family of
acquired metalloenzymes. Although VIM-1 shares
less than 30% amino acid identity with the IMP
enzymes, it possesses the same broad-spectrum
profile, including all b-lactams except aztreonam.
Resistance to the monobactam aztreonam in the
original VIM-1-producing P. aeruginosa isolate was
probably due to additional mechanisms (efflux,
cephalosporinase hyperproduction) [43]. As found
for blaIMP genes, blaVIM-1 was also part of a gene
cassette inserted into a class 1 integron. This inte-
gron carried an integrase gene typical of class 1
integrons and, in addition to a blaVIM-1 gene cas-
sette, an aacA4 gene cassette encoding resistance
to aminoglycosides (Figure 1). The blaVIM-1-
containing integron was probably chromosome
located.
Very recently, the blaVIM-1 gene was also found
in an Achromobacter xylosoxydans isolate in the
same Italian hospital [44]. This isolate exhibited
broad-spectrum resistance to b-lactams, including
Figure 1 Compared structures of the class 1 integrons
from P. aeruginosa that contain the gene cassettes encoding
IMP-like and VIM-like carbapenemases. The intI integrase
gene, which encodes an integrase, is part of the 50-CS; the
30-CS located downstream of the integrated gene cas-
sette(s) includes the sulfonamide resistance gene sul1, the
quaternary ammonium resistance determinant qacED1 and
orf5 of unknown function. Inserted gene cassettes are
indicated by boxes, with an arrow indicating their
transcriptional orientation. The 59-be recombination sites
are represented by black circles and the attI1 recombina-
tion site by white circles. References for characterized
integrons are indicated as subscripts.
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Table 2 IMP-like and VIM-like carbapenemases
Enzyme Host Origin Integron GenBank no. Reference
IMP-1 Serratia marcescens Japan þ – [25,32]
Acinetobacter baumannii Japan ? – [29]
Pseudomonas aeruginosa Japan þ – [27,28]
Achromobacter xylosoxydans Japan ? – [28]
Pseudomonas putida Japan, Taiwan ? – [28,51]
Pseudomona stutzeri Taiwan ? – [51]
Klebsiella pneumoniae Japan, Singapore ? – [28,59]
IMP-2 Acinetobacter baumannii Italy þ – [35]
IMP-3 Shigella flexneri Japan þ – [37,38]
IMP-4 Acinetobacter baumannii Hong Kong þ – [39]
Citrobacter youngae China þ – [40]
IMP-5 Acinetobacter baumannii Portugal ? AAK27847 NP
IMP-6 Serratia marcescens Japan þ – [41]
IMP-7 Pseudomonas aeruginosa Canada þ AF318077 NP
IMP-8 Klebsiella pneumoniae Taiwan ? – [42]
IMP-9 Pseudomonas aeruginosa China ? AAK59385 NP
VIM-1 Pseudomonas aeruginosa Italy þ – [43]
Acinetobacter baumannii Italy þ – NP
Achromobacter xylosoxydans Italy ? – [44]
VIM-2 Pseudomonas aeruginosa France þ – [45,47]
Greece ? – [50]
Italy þ – [60]
Spain þ – [61]
Korea ? AY029772 NP
Acinetobacter baumannii Korea ? AF305559 NP
Enterobacter cloacae Korea ? AF305559 NP
Serratia marcescens Korea ? AY030343 NP
Pseudomonas putida Korea ? AF291438 NP
Acinetobacter genomosp. 3 Italy ? AF369871 NP
Pseudomonas putida Taiwan ? – [51]
Pseudomonas stutzeri Taiwan ? – [51]
VIM-3 Pseudomonas aeruginosa Taiwan ? – [51]
?, unknown; NP, not published.
Figure 2 Comparison of the avail-
able amino acid sequences for IMP-
like enzymes. The numbering is
according to that reported recently
for class B enzymes (BBL) [36].
Highlighted amino acids are those
strictly conserved among class B b-
lactamases. Dashes indicate identi-
cal amino acids. The arrow indicates
the putative position of the leader
peptide cleavage site.
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carbapenems, and harbored a 30-kb non-conjuga-
tive plasmid carrying a class 1 integron. This
integron (In70) contained four gene cassettes, three
different aminoglycoside resistance genes being
located downstream of the blaVIM-1 gene cassette
(Figure 1). As observed for In31 carrying the
blaIMP-1 gene cassette, In70 is flanked by inverted
repeats, and a truncated tni module was detected
in its 30-part. Thus, In70 can also be considered as a
member of the group of class 1 integrons asso-
ciated with defective transposon derivatives ori-
ginating from Tn402-like elements.
BlaVIM-2 was identified first in southern France
(Marseilles), not far from Italy, from a P. aeruginosa
isolate in a blood culture of a neutropenic patient
in 1996 [45]. This isolate was resistant to most b-
lactams, including ceftazidime, cefepime and imi-
penem, whereas it remained susceptible to aztreo-
nam. VIM-2 is closely related to VIM-1 (90% amino
acid identity) and was encoded by a gene cassette
that was the only resistance gene within the iden-
tified class 1 integron In56 (Figure 1). BlaVIM-2 was
located on a c. 45-kb plasmid. This plasmid was
transferable by electroporation from P. aeruginosa
to P. aeruginosa. Although hydrolysis profiles of
VIM-1 and VIM-2 were similar for most b-lactam
substrates, kinetic parameters for benzylpenicillin,
ceftazidime and cefepime were different [46].
Thus, the structural differences between VIM-1
and VIM-2 may be functionally relevant [46].
Despite a consistent degree of sequence identity
between blaVIM-1 and blaVIM-2, the 59-bes associated
with these genes differed in size and structure.
This observation raises the question of a different
origin of blaVIM-1 and blaVIM-2 gene cassettes as well
as the corresponding carbapenemase genes. The
GþC content of blaVIM-1/VIM-2, averaging 56%,
does not provide any clue to the putative origin
of these genes, since it is known that the GþC
content of naturally occurring b-lactamase genes is
not always related to that of housekeeping genes of
a given species (see, for example, blaSHV and K.
pneumoniae genes).
Since VIM-1- and VIM-2-positive P. aeruginosa
isolates were isolated from the same southern part
of Europe, a regional outbreak of P. aeruginosa
producing related enzymes was not ruled out.
However, two other P. aeruginosa isolates were
subsequently found in the Paris area that harbored
the same blaVIM-2 gene cassette [47]. In this latter
case, the blaVIM-2 gene cassette formed part of
different class 1 integrons, underlining its spread
(Figure 1). The blaVIM-2-positive integrons carried a
variety of aminoglycoside resistance genes in
addition to the sulfonamide resistance gene
usually found in the 30-CS.
A retrospective epidemiologic study in the
hospital in Marseilles, France, where the first
VIM-2-producing P. aeruginosa strain was isolated
revealed that, from 1996 to 1998, 20 other VIM-
2-positive P. aeruginosa isolates had been isolated,
from patients hospitalized in different units. These
isolates had indistinguishable genotypic patterns
(personal data). Similarly, VIM-like-producing P.
aeruginosa isolates were found to be the source of
outbreaks in two university hospitals in Italy and
in Greece during the same period [48–50]. In
Greece, VIM-2 had been also identified, whereas
VIM-1 was identified in Italy. Additionally, a P.
aeruginosa strain that encodes a plasmid-mediated
VIM-2 enzyme has been identified recently from
Barcelona in Spain [61].
Very recently, VIM-2 and a novel variant of the
VIM series, VIM-3, have been identified in P.
aeruginosa isolates in Taiwan [51]. The VIM-3
amino acid sequence differs from that of VIM-2
by two amino acid changes. The blaVIM-3 gene was
chromosomal [51]. Identication of a VIM-type
enzyme outside Europe supported the idea of a
possible worldwide spread of carbapenemases of
the IMP as well as of the VIM series.
Detailed analysis of metalloenzyme-producing
P. aeruginosa isolates revealed that they were
involved in serious infections such as septicemia
and pneumonia and that carbapenem-containing
therapy may fail [45,48]. Expression of these b-
lactamase genes may vary. Senda et al. reported,
for example, for several Pseudomonas isolates
involved in multifocal outbreaks, that the MIC
values of imipenem ranged from 2 to >128 mg/
L [27]. This variability of MIC values may explain
the difficulty in detecting IMP- or VIM-positive
isolates in a clinical laboratory, especially among
Enterobacteriaceae [28]. Clinical microbiologists
should be aware that Gram-negative isolates,
including Enterobacteriaceae, A. baumannii and
Pseudomonas species with borderline susceptibility
to carbapenems, could be true carbapenemase
producers. Difficulties in clinical detection,
together with the plasmid, integron and some-
times transposon location of these carbapenemase
genes, may enhance their spread. Thus, suspicious
isolates should be tested for carbapenemase
activity in reference laboratories. Detection of
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metalloenzyme producers may also be based on a
double disk synergy test using carbapenems and
ion chelators [52,53].
T H E O X A C I L L I N A S E S W I T H
C A R B A P E N E M A S E P R O P E R T Y
Recently, five oxacillinases that confer some
degree of resistance to carbapenems have been
identified. These oxacillinases were from A. bau-
mannii isolates from different parts of the world.
OXA-23 (also named ARI-1 [54]) and OXA-27,
from Scotland and Singapore, respectively
[54,55], have 99% amino acid identity, whereas
they share only 60% identity with a second group
of oxacillinases with carbapenem-hydrolyzing
properties consisting of OXA-24 (Spain), OXA-25
(Spain) and OXA-26 (Belgium), the latest enzymes
differing only by a few amino acid substitutions
[56]. An unsequenced oxacillinase with carbape-
nemase activity had been identified in France [57],
and we have recently isolated a point-mutant
derivative of OXA-26 with carbapenemase activity
from an A. baumannii isolate from a patient trans-
ferred from Portugal (personal data) hospitalized
in France.
The hydrolysis profiles of these oxacillinases are
very similar. They hydrolyze imipenem and mer-
openem weakly, and do not hydrolyze extended-
spectrum cephalosporins and aztreonam (Table 1).
Their activity is inhibited by clavulanic acid, an
uncommon property for oxacillinases, except for
OXA-23, which is resistant to clavulanic acid.
OXA-24 and OXA-27 hydrolyze benzylpenicillin
and cephaloridine, while hydrolysis of oxacillin
and cloxacillin is not detectable [55]. The amino
acid sequence analysis of these oxacillinases may
indicate that a Y-to-F substitution (position 154) in
the YGN typical motif of oxacillinases may explain
part of the carbapenem hydrolysis activity of these
enzymes [54–56].
A careful comparison of MICs of b-lactams
for oxacillinase-producing clinical strains and
those for E. coli recombinant strains once the
oxacillinase genes are cloned and expressed indi-
cates that these oxacillinases have weak carbape-
nemase activity. These enzymes may contribute
to carbapenem resistance if other carbapenem
resistance mechanisms are present, such as imper-
meability or efflux. There has been a report of a
nosocomial outbreak involving such oxacillinases
[58].
While most (if not all) oxacillinase genes form
part of gene cassettes in class 1 integrons, the
genetic support of these oxacillinase genes remains
unclear. While blaOXA-23 was not found in a typical
integron, an imperfect inverted repeat sequence
similar to known 59-bes and two GTTA sequence
recombination sites in the 50- and 30-ends of the
gene were identified in its 30-downstream-located
region, thus suggesting that blaOXA-23 was a form
of gene cassette [54]. While blaOXA-24 was likely to
be chromosomally located, the genetic support of
the other oxacillinase/carbapenemase genes is
unknown. The fact that these oxacillinases have
been reported so far only from A. baumannii iso-
lates remains intriguing.
C O N C L U S I O N
This review emphasizes that acquired carbapene-
mases are increasingly reported worldwide
among nosocomial and community-acquired
Gram-negative aerobes. Enzymes that may be
clinically worrying are of the IMP and VIM series
in P. aeruginosa and Enterobacteriaceae and of the
oxacillinase type in Acinetobacter baumannii. These
enzymes confer resistance to carbapenems, once
expressed from Gram-negative species that pos-
sess either a naturally occurring (P. aeruginosa,
Acinetobacter sp.) or an acquired (Enterobacteria-
ceae) low level of outer membrane permeability/
efflux. The only exception would be the recently
reported plasmid-encoded class A enzyme KPC-1
from a K. pneumoniae isolate that confers high-level
resistance to carbapenems by itself.
Thus, clinical detection of carbapenemase pro-
ducers remains difficult based on a simple pheno-
typic analysis of antibiotic susceptibility testing.
With the exception of the rare class A enzymes
with carbapenemase activity, detection of these
enzymes by a synergy test based on clavulanate-
and imipenem-containing disks remains elusive.
A PCR-based technique may be used for detec-
tion of known metalloenzymes. Detection of
acquired class B enzymes may be based on the
degenerated primers IMP-A (50-gaa ggy gtt tat
gtt cat ac-30) and IMP-B (50-gta mgt ttc aag agt
gat gc-30) for blaIMP-like genes, and on primers
VIM-B (50-atg gtg ttt ggt cgc ata tc-30) and VIM-F
(50-tgg gcc att cag cca gat c-30) for the blaVIM-like
genes.
One of the most interesting aspects of further
studies will be to estimate precisely the prevalence
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of carbapenemases among clinically relevant
Gram-negative isolates and to analyze the selec-
tion power of b-lactam and non-b-lactam antibio-
tics, since the carbapenemase genes are often
physically linked to at least aminoglycoside resis-
tance genes in integron structures.
The origin of these carbapenemase genes
remains unknown. It is very likely that Enterobac-
teriaceae do not represent the natural reservoir of
these enzymes. Determination of the reservoirs,
which may be environmental, may help to prevent
dissemination of carbapenemase genes and may
provide insights into the molecular mechanism of
integron and gene cassette formation.
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